Phase I clinical trial of idiotypic DNA vaccine administered as a complex with polyethylenimine to patients with B-cell lymphoma

Human Vaccines and Immunotherapeutics

Volumn 13, Issue 6, 2017, Pages 1398-1403

  Meleshko, A N ^a   Petrovskaya, N A ^b   Savelyeva, N ^c   Vashkevich, K P ^a   Doronina, S N ^a   Sachivko, N V ^b  

^a Belarusian Research Center for Pediatric Oncology Hematology and Immunology   (Belarus)

^b NN Alexandrov National Cancer Center of Belarus   (Belarus)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

cancer vaccine; DNA vaccine; idiotype; lymphoma; polyethylenimine

Indexed keywords

DNA VACCINE; GAMMA INTERFERON; PHYTOHEMAGGLUTININ; POLYETHYLENEIMINE; AUTOANTIBODY; CAPSID PROTEIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOLOGICAL ADJUVANT; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA;

B CELL LYMPHOMA; BONE MARROW BIOPSY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HUMORAL IMMUNITY; INNATE IMMUNITY; LYMPH NODE BIOPSY; LYMPHOCYTIC LYMPHOMA; MARGINAL ZONE LYMPHOMA; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; NOTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION MAPPING; SPECTROPHOTOMETRY; TUMOR IMMUNOGENICITY; WALDENSTROEM MACROGLOBULINEMIA; ADOLESCENT; ADULT; AGED; BLOOD; FEMALE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL (TOPIC); POTEXVIRUS; T LYMPHOCYTE; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CAPSID PROTEINS; CHEMOKINE CCL20; CLINICAL TRIALS, PHASE I AS TOPIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYETHYLENEIMINE; POTEXVIRUS; T-LYMPHOCYTES; VACCINES, DNA; YOUNG ADULT;

EID: 85015702069     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2017.1285477     Document Type: Note

References (42)

1. Okeanov AE, Moiseyev PI, Levin LF, et al.(2005–2014) [Statistics of oncological diseases in the Republic of Belarus (2005–2014)]. Minsk, Belarus:N.N. Alexandrov National Cancer Centre of Belarus; 2015. Russian.
2. Armitage JO. Non-Hodgkin lymphomas (2nd ed). Philadelphia:Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010.
3. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992;327(17):1209-1215; PMID:1406793; https://doi.org/10.1056/NEJM199210223271705
4. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med. 1999;5(10):1171-1177; PMID:10502821; https://doi.org/10.1038/13928
5. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, Denney DW, Levy R. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2009;50(1):37-46; PMID:19125383; https://doi.org/10.1080/10428190802563355
6. Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, et al. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J Natl Cancer Inst. 2006;98(18):1292-1301
7. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, et al. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J Clin Oncol. 2006;24(19):3107-3112
8. Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol. 2011;29(20):2787-2794
9. Kretzschmar T, Aoustin L, Zingel O, Marangi M, Vonach B, Towbin H, Geiser M. High-level expression in insect cells and purification of secreted monomeric single-chain Fv antibodies. J Immunol Methods. 1996;195(1–2):93-101; PMID:8814324; https://doi.org/10.1016/0022-1759(96)00093-2
10. McCormick AA, Reinl SJ, Cameron TI, Vojdani F, Fronefield M, Levy R, Tusé D. Individualized human scFv vaccines produced in plants:humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods. 2003; 278(1-2):95-104; PMID:12957399; https://doi.org/10.1016/S0022-1759(03)00208-4
11. Tusé D, Ku N, Bendandi M, Becerra C, Collins R, Jr, Langford N, Sancho SI, López-Díaz de Cerio A, Pastor F, Kandzia R, et al. Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma. Biomed Res Int. 2015; 2015:648143; PMID:26425548; https://doi.org/10.1155/2015/648143
12. Coban C, Koyama S, Takeshita F, Akira S, Ishii KJ. Molecular and cellular mechanisms of DNA vaccines. Hum Vaccin. 2008; 4(6):453-457
13. Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines:precision tools for activating effective immunity against cancer. Nat Rev Cancer. 2008;8(2):108-120; PMID:18219306; https://doi.org/10.1038/nrc2326
14. Stevenson FK, Rice J, Ottensmeier CH, Thirdborough SM, Zhu D. DNA fusion gene vaccines against cancer:from the laboratory to the clinic. Immunol Rev. 2004;199:156-180; PMID:15233733; https://doi.org/10.1111/j.0105-2896.2004.00145.x
15. Stevenson FK, Mander A, Chudley L, Ottensmeier CH. DNA fusion vaccines enter the clinic. Cancer Immunol Immunother. 2011;60(8):1147-1151; PMID:21644035; https://doi.org/10.1007/s00262-011-1042-2
16. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L, Trial watch:DNA vaccines for cancer therapy. Oncoimmunology. 2013;2(4):e23803; PMID:23734328; https://doi.org/10.4161/onci.23803
17. Patel KG, Ng PP, Levy S, Levy R, Swartz JR. Escherichia coli-based production of a tumor idiotype antibody fragment-tetanus toxin fragment C fusion protein vaccine for B cell lymphoma. Protein Expr Purif. 2011; 75(1):15-20; https://doi.org/10.1016/j.pep.2010.09.005
18. Guo JH, Fan MW, Sun JH, Jia R. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Int Immunopharmacol. 2009;9(7-8):925-930; https://doi.org/10.1016/j.intimp.2009.03.019
19. Savelyeva N, Munday R, Spellerberg MB, Lomonossoff GP, Stevenson FK. Plant viral genes in DNA idiotypic vaccines activate linked CD4+ T-cell mediated immunity against B-cell malignancies. Nat Biotechnol. 2001;19(8):760-764; PMID:11479570; https://doi.org/10.1038/90816
20. Chen CG, Lu Y-T, Lin M, Savelyeva N, Stevenson FK, Zhu D. Amplification of immune responses against a DNA-delivered idiotypic lymphoma antigen by fusion to the B subunit of E. coli heat labile toxin. Vaccine. 2009; 27(32):4289-4296
21. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 2002;62(20):5845-5852. PMID:12384547 PMID:12384547 PMID:12384547
22. Oh Y-K, Suh D, Kim JM, Choi HG, Shin K, Ko JJ. Polyethylenimine-mediated cellular uptake, nucleus trafficking and expression of cytokine plasmid DNA. Gene Ther. 2002;9(23):1627-1632; PMID:12424615; https://doi.org/10.1038/sj.gt.3301735
23. Ma Y-F, Yang Y-W. Delivery of DNA-based cancer vaccine with polyethylenimine. Eur J Pharm Sci. 2010;40(2):75-83; https://doi.org/10.1016/j.ejps.2010.02.009
24. Garzon MR, Berraondo P, Crettaz J, Ochoa L, Vera M, Lasarte JJ, Vales A, Van Rooijen N, Ruiz J, Prieto J, et al. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex. Vaccine. 2005;23(11):1384-1392
25. Oh YK, Kim JP, Yoon H, Kim JM, Yang JS, Kim CK. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther. 2001;8:1587-1592; PMID:11704820; https://doi.org/10.1038/sj.gt.3301516
26. Grant E V., Thomas M, Fortune J, Klibanov AM, Letvin NL. Enhancement of plasmid DNA immunogenicity with linear polyethylenimine. Eur J Immunol. 2012;42(11):2937-2948; PMID:22886924; https://doi.org/10.1002/eji.201242410
27. Houot R, Levy R. Vaccines for lymphomas:idiotype vaccines and beyond. Blood Rev. 2009;23(3):137-142; https://doi.org/10.1016/j.blre.2008.09.001
28. Meleshko AN, Vashkevich KP, Fomina EG, Scheslenok EP, Schkolina TV, Sergeev GV. Cloning of variable fragments of tumor immunoglobulin, assembling and expressing of human SCFV protein in E. coli for anti-idiotype vaccination. Exp Oncol. 2013;35(1):8-14
29. Jacobus AP, Gross J. Optimal cloning of PCR fragments by homologous recombination in Escherichia coli. PLoS One. 2015;10(3):1-17; https://doi.org/10.1371/journal.pone.0119221
30. Saltzman WM, Shen H, Brandsma JL. DNA Vaccines:Methods and Protocols. SECOND EDI. (Hackworth J, ed.). Totowa, New Jersey:Humana Press Inc; 2006
31. Meleshko AN, Savva NN, Fedasenka UU, Romancova AS, Krasko OV, Eckert C, von Stackelberg A, Aleinikova OV. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols. Leuk Res. 2011;35(10):1312-1320; https://doi.org/10.1016/j.leukres.2011.04.013
32. van der Velden VHJ, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements:guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21(4):604-611; PMID:17287850
33. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines:developing new strategies against cancer. J Biomed Biotechnol. 2010;2010:174378; PMID:20368780; https://doi.org/10.1155/2010/174378
34. Best SR, Peng S, Juang CM, Hung CF, Hannaman D, Saunders JR, Wu TC, Pai SI. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine. 2009;27(40):5450-5459
35. Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier CH. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther. 2009;20(11):1269-1278; PMID:19619001; https://doi.org/10.1089/hum.2009.067
36. van den Berg JH, Nuijen B, Schumacher TN, Haanen JB, Storm G, Beijnen JH, Hennink WE. Synthetic vehicles for DNA vaccination. J Drug Target. 2010;18(1):1-14; PMID:19814658; https://doi.org/10.3109/10611860903278023
37. Bolhassani A, Safaiyan S, Rafati S. Improvement of different vaccine delivery systems for cancer therapy. Mol Cancer. 2011;10(1):3; PMID:21211062; https://doi.org/10.1186/1476-4598-10-3
38. Di Gioia S, Conese M. Polyethylenimine-mediated gene delivery to the lung and therapeutic applications. Drug Des Devel Ther. 2009;2(2):163-188; PMID:19920904
39. Thomas SK, Kwak LW. Lymphoma vaccine therapy:next steps after a positive, controlled phase III clinical trial. Semin Oncol. 2012;39(3):253-262; https://doi.org/10.1053/j.seminoncol.2012.02.014
40. Savelyeva N, Allen A, Chotprakaikiat W, Harden E, Jobsri J, Godeseth R, Wang Y, Stevenson F, Ottensmeier C. Linked CD4 T Cell Help:Broadening Immune Attack Against Cancer by Vaccination. Curr Top Microbiol Immunol. 2016;351(January):139-157
41. Jobsri J, Allen A, Rajagopal D, Shipton M, Kanyuka K, Lomonossoff GP, Ottensmeier C, Diebold SS, Stevenson FK1, Savelyeva N1. Plant virus particles carrying tumour antigen activate TLR7 and Induce high levels of protective antibody. PLoS One. 2015;10(2):e0118096; PMID:25692288; https://doi.org/10.1371/journal.pone.0118096
42. Chudley L, McCann KJ, Coleman A, Cazaly AM, Bidmon N, Britten CM, van der Burg SH, Gouttefangeas C, Jandus C, Laske K, et al. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining. Cancer Immunol Immunother. 2014;63(11):1199-1211; https://doi.org/10.1007/s00262-014-1593-0